Pelvic Inflammatory Disease Clinical Trial
Official title:
An Open-Lable Multicenter Prospective Non-Randomized Trial to Assess the Efficacy and Safety of Morinidazole With Levofloxacin and Sequential of Levofloxacin in Women With Pelvic Inflammatory Disease
Verified date | November 2017 |
Source | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Contact | Shixuan Wang |
Phone | 02783663078 |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To assess the efficacy, safety and Population Pharmacokinetic (PPK) of morinidazole and sodium chloride injection with levofloxacin hydrochloride and sodium chloride injection sequential of levofloxacin hydrochloride tablets in women with pelvic inflammatory disease: An Open-Lable Multicenter Prospective Non-Randomized Trial
Status | Recruiting |
Enrollment | 469 |
Est. completion date | December 2018 |
Est. primary completion date | December 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - women between 18 and 65 years old - patients with the diagnosis of PID: 1. sexually active women or women have the risk of sexually transmitted infections, and 2. lower abdominal pain symptoms, and 3. lower abdominal tenderness, and adnexal and cervical motion tenderness on bimanual vaginal examination, and 4. as well as at least one of the following signs: 1. pyrexia (axillary temperature > 37.8 °C) 2. mucopurulent cervical or vaginal discharge 3. an elevated vaginal discharge white blood cell count (WBC) 4. an elevated erythrocyte sedimentation rate 5. an elevated C-reactive protein 6. laboratory tests confirmed the presence of Chlamydia trachomatis infection in the cervix 7. WBC > 10*109/L on routine blood examination 5. Voluntary signing of written informed consent Exclusion Criteria: - patients with a history of antibiotic therapy for more than 3 days - patients with any condition likely to require surgery - Cervical / vaginal discharge examination found Gonorrhea gonorrhea - patients with an allergy to nitroimidazole or quinolones - patients with brain and spinal cord lesions, epilepsy and various organ sclerosis - patients who received an abortion or surgery of uterus, cervix, abdomen within 1 month - serious chronic liver disease (Child-Pugh graded C-class) - patients with hematopoietic dysfunction or chronic alcoholism - any factors that increase the risk of QTc prolongation or arrhythmia - ALT and / or AST = 2 times the ULN - serum creatinine = 1.5 times the ULN - total bilirubin = 1.5 times the ULN - ECG QTc interval> 470ms - any clinically significant abnormalities in rhythms, conduction or morphology of resting ECGs - Pregnant women, breastfeeding women, women of childbearing age without effective contraceptive |
Country | Name | City | State |
---|---|---|---|
China | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | Hubei |
Lead Sponsor | Collaborator |
---|---|
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical cure Rate | Clinical cure Rate (according to symptoms and signs) at 7-30 days post-therapy | 7-30 days | |
Secondary | The incidence of AE | The incidence of adverse events | 14 days | |
Secondary | Incidence of ADR | Incidence of adverse reactions | 14 days | |
Secondary | Incidence of serious ADR | Incidence of serious adverse reactions | 14 days | |
Secondary | Bacteriological response(Bacterial elimination rate) | Bacteriological response (on the first day post-therapy, at 7-30 days post-therapy) | the first day and 7-30 days | |
Secondary | PPK parameters | Area under the plasma concentration versus time curve (AUC) of morinidazole | 14 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04723069 -
Efficacy and Safety of Fuke Qianjin Capsule in Patients With Pelvic Inflammatory Diseases
|
Phase 2 | |
Completed |
NCT01671280 -
Drug Use Investigation Of Azithromycin IV For Community-Acquired Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)
|
N/A | |
Completed |
NCT00115388 -
Community-Based Trial of Screening for Chlamydia Trachomatis to Prevent Pelvic Inflammatory Disease
|
N/A | |
Not yet recruiting |
NCT02972151 -
Clinical Research of TCM on Pelvic Inflammatory Disease Sequelae
|
Phase 2 | |
Completed |
NCT01160640 -
The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)
|
Phase 2 | |
Completed |
NCT01236131 -
The Role of Novel Organisms in Acute Endometritis
|
N/A | |
Active, not recruiting |
NCT03994055 -
Effect of an Anti-inflammatory Diet on Patients With Cervical Cancer
|
N/A | |
Completed |
NCT00871494 -
Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan
|
Phase 3 | |
Completed |
NCT00783419 -
Rate of Pelvic Inflammatory Disease at St. Michael's Hospital
|
||
Completed |
NCT01799356 -
Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials
|
Phase 4 | |
Recruiting |
NCT05408624 -
Pilot Study Evaluating Outpatient Management of Tubo-ovarian Abscesses
|
||
Completed |
NCT01241110 -
To Compare Ofloxacin With Azitromycin for Pelvic Inflammatory Disease (PID) Treatment
|
Phase 4 | |
Completed |
NCT00453349 -
A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease
|
Phase 3 | |
Recruiting |
NCT04234945 -
Effect of Prophylactic Antibiotics for Hysterosalpingography on Post Procedure Morbidity
|
N/A | |
Recruiting |
NCT06360965 -
Clinical Trial of Acupoint Application in Improving the Sequelae of Pelvic Inflammatory Disease and Chronic Pelvic Pain
|
N/A | |
Recruiting |
NCT05648747 -
Pelvic Inflammatory Disease in COVID-19 Era
|
||
Completed |
NCT01793584 -
Surgical Success After Laparoscopic vs Abdominal Hysterectomy
|
N/A | |
Completed |
NCT01299259 -
Improving Primary Care Follow-up for Patients With Pelvic Inflammatory Disease
|
N/A | |
Completed |
NCT03054402 -
First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845
|
Phase 1 | |
Active, not recruiting |
NCT03828994 -
Technology Based Community Health Nursing(TECH-N) to Prevent Recurrent STIs After PID II
|
N/A |